ACRX - AcelRx Pharmaceuticals Inc Stock Price, Fair Value and News

1.08USD0.00 (0.00%)Delayed

Market Summary

USD1.080.00

Delayed

0.00%

ACRX Stock Price

View Fullscreen

ACRX RSI Chart

ACRX Valuation

Market Cap

18.4M

Price/Earnings (Trailing)

-1.29

Price/Sales (Trailing)

0.19

EV/EBITDA

-0.61

Price/Free Cashflow

-1.21

ACRX Price/Sales (Trailing)

ACRX Profitability

EBT Margin

-11.49%

Return on Equity

-86.93%

Return on Assets

-49.35%

Free Cashflow Yield

-82.41%

ACRX Fundamentals

ACRX Revenue

Revenue (TTM)

89.6M

ACRX Earnings

Earnings (TTM)

-14.2M

Earnings Growth (Yr)

51.5%

Earnings Growth (Qtr)

12.46%

Breaking Down ACRX Revenue

Last 7 days

6.9%

Last 30 days

6.9%

Last 90 days

-13.6%

Trailing 12 Months

25.6%

How does ACRX drawdown profile look like?

ACRX Financial Health

Current Ratio

5.97

ACRX Investor Care

Shares Dilution (1Y)

55.55%

Diluted EPS (TTM)

-1.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	89.6M	0	0	0
2022	23.1M	43.4M	63.7M	84.1M
2021	5.5M	3.1M	3.6M	2.8M
2020	2.2M	4.2M	5.0M	5.4M
2019	2.4M	2.6M	2.8M	2.5M
2018	5.2M	3.4M	2.3M	2.2M
2017	17.4M	15.6M	13.7M	8.0M
2016	22.1M	24.7M	12.7M	17.4M
2015	8.7M	12.2M	15.8M	19.3M
2014	23.4M	17.4M	11.3M	5.2M
2013	3.0M	3.2M	3.6M	29.5M
2012	1.4M	1.7M	2.1M	2.4M
2011	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AcelRx Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 13, 2023	angotti vincent j.	bought	7,268	0.7268	10,000	chief executive officer
Oct 10, 2023	hoffman stephen j	acquired	-	-	581	-
Oct 10, 2023	afable richard	acquired	-	-	581	-
Oct 10, 2023	adams adrian	acquired	-	-	581	-
Oct 10, 2023	broadfoot jill marie	acquired	-	-	581	-
Oct 10, 2023	rosen howard b	acquired	-	-	581	-
Oct 10, 2023	wan mark a	acquired	-	-	581	-
Oct 10, 2023	bozilenko marina	acquired	-	-	581	-
Sep 11, 2023	angotti vincent j.	bought	7,950	0.795	10,000	chief executive officer
Aug 25, 2023	palmer pamela p	sold	-8,104	1.089	-7,442	chief medical officer

Which funds bought or sold ACRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	29.47	7,315	16,297	-%
May 15, 2024	Royal Bank of Canada	added	795,590	156,000	156,000	-%
May 15, 2024	CITADEL ADVISORS LLC	added	37.6	20,400	42,375	-%
May 15, 2024	CANTOR FITZGERALD, L. P.	sold off	-100	-3,488,480	-	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	sold off	-100	-143,325	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-15,473	-	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-19.5	233,143	2,052,300	0.12%
May 15, 2024	Tower Research Capital LLC (TRC)	added	6.03	2,724	8,330	-%
May 15, 2024	Rock Springs Capital Management LP	unchanged	-	93,356	325,954	0.01%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-16.00	-	-%

Are Funds Buying or Selling ACRX?

Are funds buying ACRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACRX

No. of Funds

Unveiling AcelRx Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	890,346	SC 13G/A
Feb 13, 2024	lind global fund ii lp	4.2%	735,296	SC 13G/A
Jan 23, 2024	nantahala capital management, llc	11.8%	1,992,519	SC 13D
Aug 01, 2023	lind global fund ii lp	6.5%	1,102,944	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	864,328	SC 13G/A
Feb 15, 2022	armistice capital, llc	9.99%	12,314,479	SC 13G
Jan 27, 2022	bml investment partners, l.p.	0.0%	0	SC 13G/A
Jul 12, 2021	blackrock inc.	1.9%	2,266,040	SC 13G/A
Feb 10, 2021	bml investment partners, l.p.	5.3%	5,200,000	SC 13G/A
Jan 29, 2021	blackrock inc.	5.7%	5,640,946	SC 13G/A

Recent SEC filings of AcelRx Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 19, 2024	8-K	Current Report
Mar 21, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	10-K	Annual Report

Peers (Alternatives to AcelRx Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

AcelRx Pharmaceuticals Inc News

Latest updates

AcelRx Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-100.0%	-	5,511,000	-	-	84,052,000	42,027,000	2,000	1,862,000	443,000	511,000	738,000	1,368,000	2,924,000	386,000	294,000	608,000	941,000	627,000	613,000	377,000	818,000
Costs and Expenses	-20.5%	4,237,000	5,328,000	5,886,000	4,523,000	9,955,000	4,936,000	-12,112,000	10,495,000	10,458,000	9,653,000	9,982,000	10,405,000	9,758,000	16,234,000	15,467,000	14,142,000	14,302,000	12,583,000	11,590,000	9,705,000	7,971,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,590,000	9,705,000	7,971,000
S&GA Expenses	-34.5%	2,804,000	4,281,000	5,227,000	3,724,000	3,960,000	4,100,000	-9,490,000	8,640,000	8,694,000	7,644,000	7,846,000	7,598,000	7,575,000	13,311,000	12,786,000	10,936,000	11,329,000	9,976,000	7,648,000	5,188,000	3,944,000
R&D Expenses	36.9%	1,433,000	1,047,000	612,000	799,000	1,094,000	836,000	-674,000	1,416,000	724,000	969,000	836,000	956,000	813,000	1,412,000	1,063,000	1,058,000	1,163,000	1,377,000	2,704,000	3,642,000	3,278,000
EBITDA Margin	-112.8%	-0.11	0.90	0.96	1.08	1.52	-0.57	-4.59	-8.89	-9.65	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	119,000	188,000	245,000	293,000	390,000	369,000	538,000	614,000	672,000	754,000	824,000	872,000	855,000	831,000	828,000	500,000	376,000	459,000	529,000	586,000
Income Taxes	-	-	-	-1,000	11,000	3,000	-	-	-	5,000	-	-	-	4,000	-	-	-	3,000	-	-	-	2,000
Earnings Before Taxes	-	-	-	3,885,000	-6,739,000	70,666,000	-	10,030,000	-8,375,000	-9,846,000	-	-8,918,000	-8,930,000	-6,602,000	-	-14,423,000	-12,731,000	-12,409,000	-	-12,558,000	-12,458,000	-10,539,000
EBT Margin	-113.2%	-0.11	0.87	0.93	1.03	1.44	-0.74	-6.07	-10.15	-11.21	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	51.5%	-3,954,000	-8,152,000	-7,484,000	-6,750,000	70,663,000	-8,674,000	-7,917,000	-8,375,000	-9,851,000	-8,956,000	-8,918,000	-8,930,000	-6,606,000	-15,925,000	-14,423,000	-12,731,000	-12,412,000	-13,674,000	-12,558,000	-12,458,000	-
Net Income Margin	-129.4%	-0.16	0.54	0.57	0.74	1.05	-1.51	-12.46	-10.16	-11.98	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	46.1%	-2,883,000	-5,350,000	-5,461,000	-5,396,000	-8,815,000	-9,023,000	-8,032,000	-4,127,000	-9,938,000	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	41.1%	29.00	20.00	23.00	18.00	26.00	47.00	48.00	56.00	72.00	78.00	72.00	80.00	87.00	66.00	66.00	67.00	77.00	91.00	105	115	113
Current Assets	72.7%	20.00	12.00	14.00	9.00	17.00	25.00	25.00	32.00	43.00	50.00	52.00	59.00	71.00	47.00	48.00	49.00	58.00	72.00	86.00	97.00	95.00
Cash Equivalents	111.9%	12.00	6.00	13.00	7.00	13.00	15.00	13.00	15.00	22.00	8.00	8.00	21.00	34.00	22.00	20.00	22.00	24.00	15.00	22.00	65.00	73.00
Inventory	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	2.00
Net PPE	-	-	-	-	-	-	-	11.00	11.00	16.00	5.00	16.00	16.00	16.00	16.00	14.00	14.00	15.00	15.00	14.00	13.00	12.00
Liabilities	97.7%	12.00	6.00	5.00	7.00	12.00	26.00	21.00	23.00	110	114	115	116	115	122	124	128	133	133	133	134	121
Current Liabilities	-25.9%	3.00	5.00	4.00	4.00	9.00	14.00	16.00	18.00	17.00	19.00	17.00	15.00	16.00	18.00	17.00	16.00	16.00	14.00	11.00	8.00	19.00
Long Term Debt	-	-	-	-	-	-	-	-	-	3.00	5.00	7.00	9.00	11.00	13.00	15.00	17.00	19.00	21.00	22.00	24.00	-
LT Debt, Current	-	-	-	-	-	3.00	5.00	8.00	10.00	9.00	8.00	9.00	9.00	9.00	9.00	9.00	9.00	7.00	5.00	2.00	-	10.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	3.00	5.00	7.00	9.00	11.00	13.00	15.00	17.00	19.00	21.00	22.00	24.00	-
Shareholder's Equity	15.8%	16.00	14.00	18.00	10.00	14.00	22.00	27.00	33.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-0.9%	-448	-444	-439	-438	-433	-425	-418	-411	-482	-473	-465	-457	-447	-438	-429	-420	-414	-398	-383	-370	-358
Additional Paid-In Capital	1.3%	464	458	458	449	448	448	446	445	444	438	423	421	420	383	372	360	359	357	355	352	351
Shares Outstanding	0.2%	17.00	17.00	17.00	11.00	11.00	8.00	7.00	7.00	7.00	7.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	12.00	-	-	-	36.00	-	-	-	161	-	-	-	95.00	-	-	-	197	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	27.0%	-2,883	-3,949	-2,960	-5,333	-5,250	-5,413	-5,238	-8,746	-8,934	-8,004	-3,943	-8,347	-9,708	-6,327	-8,124	-9,690	-14,364	-14,155	-11,466	-12,319	-13,240
Share Based Compensation	-2.9%	302	311	378	471	569	652	701	753	783	1,127	1,221	1,172	1,089	1,084	1,104	1,090	1,146	1,278	1,326	1,346	1,107
Cashflow From Investing	25.2%	-2,730	-3,651	-	2,723	400	2,660	4,442	9,172	20,176	-4,439	-6,652	2,393	-17,425	5,775	-1,214	6,928	22,650	6,889	-33,206	-10,617	371
Cashflow From Financing	17767.6%	12,014	-68.00	8,939	-3,333	-2,072	5,296	-1,637	-2,083	-2,083	11,835	-2,461	-2,082	34,222	7,853	7,522	665	916	1.00	1,550	14,695	-1,794

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Costs and Expenses [Abstract]
Research and development	$ 1,433	$ 1,047
Selling, general and administrative	2,804	4,281
Total operating costs and expenses	4,237	5,328
Nonoperating Income (Expense) [Abstract]
Interest expense	0	(119)
Interest income and other income, net	220	200
Gain on sale of future payments	1,246	0
Change in fair value of warrant liability	(1,002)	5,311
Non-cash interest expense on liability related to sale of future payments	(181)	0
Total other income (expense), net	283	5,392
Net (loss) income from continuing operations	(3,954)	64
Net loss from discontinued operations– See Note 3	0	(8,216)
Net loss	$ (3,954)	$ (8,152)
Basic and diluted, continuing operations (in dollars per share)	$ (0.16)	$ 0
Basic and diluted, discontinued operations (in dollars per share)	0	(0.75)
Basic and diluted loss per share (in dollars per share)	$ (0.16)	$ (0.75)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 10 (in shares)	24,721,964	10,893,954
Product [Member]
Operating Costs and Expenses [Abstract]
Loss from operations	$ (4,237)	$ (5,328)

ACRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

^[1]

Assets, Current [Abstract]

Cash and cash equivalents

$ 12,122

$ 5,721

Short-term investments

6,462

3,660

Prepaid expenses and other current assets

1,369

2,195

Total current assets

19,953

11,576

In-process research and development asset

8,819

Total Assets

28,772

20,395

Current Liabilities:

Accounts payable

1,274

1,336

Accrued and other liabilities

1,340

2,445

Liabilities of discontinued operations, current portion

730

731

Total current liabilities

3,344

4,512

Warrant liability

2,780

1,778

Liability related to the sale of future payments

6,314

Total Liabilities

12,438

6,290

Commitments and Contingencies

Common stock, $0.001 par value—200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 16,992,726 and 16,952,219 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively

Additional paid-in capital

464,497

458,314

Accumulated deficit

(448,180)

(444,226)

Total Stockholders’ Equity

16,334

14,105

Total Liabilities and Stockholders’ Equity

$ 28,772

$ 20,395

[1]	The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

About AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

CEO	Mr. Vincent J. Angotti
WEBSITE	acelrx.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	19

AcelRx Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for AcelRx Pharmaceuticals Inc? What does ACRX stand for in stocks?

ACRX is the stock ticker symbol of AcelRx Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AcelRx Pharmaceuticals Inc (ACRX)?

As of Fri May 17 2024, market cap of AcelRx Pharmaceuticals Inc is 18.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRX stock?

You can check ACRX's fair value in chart for subscribers.

What is the fair value of ACRX stock?

You can check ACRX's fair value in chart for subscribers. The fair value of AcelRx Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AcelRx Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AcelRx Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACRX is over valued or under valued. Whether AcelRx Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact AcelRx Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRX.

What is AcelRx Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ACRX's PE ratio (Price to Earnings) is -1.29 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AcelRx Pharmaceuticals Inc's stock?

In the past 10 years, AcelRx Pharmaceuticals Inc has provided -0.189 (multiply by 100 for percentage) rate of return.